Estradiol- and medroxyprogesterone-containing product
RxNorm 636632
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 636632 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Estradiol- and medroxyprogesterone-containing product.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
MIN
Multiple Ingredients (MIN):
Estradiol / medroxyprogesterone
(Atom ID: 12352877)
TMSY
Tall Man Lettering Synonym (TMSY):
Estradiol / medroxyPROGESTERone
(Atom ID: 12377188)
PT
Designated preferred name (PT):
Estradiol- and medroxyprogesterone-containing product
(Atom ID: 10802467)
FN
Full form of descriptor (FN):
Product containing estradiol and medroxyprogesterone (medicinal product)
(Atom ID: 10810944)
Patient Education
Estrogen and Progestin (Hormone Replacement Therapy)
Combinations of estrogen and progestin are used to treat certain symptoms of menopause. Estrogen and progestin are two female sex hormones. Hormone replacement therapy works by replacing estrogen hormone that is no longer being made by the body. Estrogen reduces feelings of warmth in the upper body and periods of sweating and heat (hot flashes), vaginal symptoms (itching, burning, and dryness) and difficulty with urination, but it does not relieve other symptoms of menopause such as nervousness or depression. Estrogen also prevents thinning of the bones (osteoporosis) in menopausal women. Progestin is added to estrogen in hormone replacement therapy to reduce the risk of uterine cancer in women who still have their uterus.
[Learn More]
* Please review the disclaimer below.